Reduced in vitro activity of ceftaroline by Etest among clonal complex 239 methicillin-resistant Staphylococcus aureus clinical strains from Australia

I. J. Abbott, A. W.J. Jenney, C. J. Jeremiah, M. Mirčeta, J. P. Kandiah, D. C. Holt, S. Y.C. Tong, D. W. Spelman

Research output: Contribution to journalArticleResearchpeer-review

10 Citations (Scopus)

Abstract

A total of 421 methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates were tested for ceftaroline susceptibility by Etest (bioMérieux). A multidrug resistant phenotype was found in 40.9%, and clonal complex 239 (CC239) was found in 33.5%. Ceftaroline nonsusceptibility (MIC, > 1.0 μg/ml) was 16.9% overall. Nonsusceptibility was significantly higher in CC239 (41.1%, 58/141) and in isolates with a multidrug resistant phenotype (35.5%, 61/172) compared with comparators (P<0.0001). Nonsusceptibility of common multidrug resistant MRSA clones limits the empirical use of ceftaroline for these infections.

Original languageEnglish
Pages (from-to)7837-7841
Number of pages5
JournalAntimicrobial Agents and Chemotherapy
Volume59
Issue number12
DOIs
Publication statusPublished - 1 Dec 2015
Externally publishedYes

Cite this